Connecticut 2023 Regular Session Status: Passed House Bipartisan · 3 R · 2 D cosponsors

HB 6831 — AN ACT CONCERNING THE OVERRIDE OF STEP THERAPY FOR CERTAIN MENTAL HEALTH CONDITIONS AND ESTABLISHING A TASK FORCE TO STUDY DATA COLLECTION EFFORTS REGARDING STEP THERAPY.

Last action — SENATE CALENDAR NUMBER 460

Track this bill free

No card. One bill, free forever — alerts when it moves.

  1. ✓
    Introduced
  2. ✓
    In Committee
  3. 3
    Passed House
  4. 4
    Passed Senate
  5. 5
    To Executive
  6. 6
    Enacted

This bill died with 2023 Regular Session. It reached “Passed House” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.

This bill is no longer active — its legislative session has ended, so there is no live prognosis. It would have to be reintroduced in the current session to move again.

Bill Text

What changed in the latest version

147 added · 39 removed

147 line(s) added, 39 removed.

→
Previous
Latest
General Assembly Raised Bill No.
House of Representatives General Assembly File No.
6831 January Session, 2023 LCO No.
334 January Session, 2023 Substitute House Bill No.
3151 Referred to Committee on INSURANCE AND REAL ESTATE Introduced by:
6831 House of Representatives, March 30, 2023 The Committee on Insurance and Real Estate reported through REP.
(INS) AN ACT CONCERNING THE OVERRIDE OF STEP THERAPY FOR CERTAIN MENTAL HEALTH CONDITIONS.
WOOD of the 29th Dist., Chairperson of the Committee on the part of the House, that the substitute bill ought to pass.
AN ACT CONCERNING THE OVERRIDE OF STEP THERAPY FOR CERTAIN MENTAL HEALTH CONDITIONS AND ESTABLISHING A TASK FORCE TO STUDY DATA COLLECTION EFFORTS REGARDING STEP THERAPY.
Such disclosure shall be made to health care providers, in writing, not less than once each calendar year and such health care provider shall display in a conspicuous and prominent location, including the provider's Internet web site and on a bulletin board in the provider's office, information regarding the override process.
Such disclosure shall be made to health care providers, in writing, not less than once each calendar year and such health care provider shall display in a sHB6831 / File No.
Any such override process shall be LCO No.
334 1 sHB6831 File No.
3151 1 of 5 Raised Bill No.6831 convenient to use by health care providers and an override request shall be expeditiously granted when an insured's treating health care provider demonstrates that the drug regimen required under step therapy (A)has beenineffective inthepast for treatment oftheinsured's medical condition, (B) is expected to be ineffective based on the known relevant physical or mental characteristics of the insured and the known characteristics of the drug regimen, (C) will cause or will likely cause an adverse reaction by or physical harm to the insured, or (D) is not in the best interest of the insured, based on medical necessity.
334 conspicuous and prominent location, including the provider's Internet web site and on a bulletin board in the provider's office, information regarding the override process.
Any such override process shall be convenient to use by health care providers and an override request shall be expeditiously granted when an insured's treating health care provider demonstrates that the drug regimen required under step therapy (A)has beenineffective inthepast for treatment oftheinsured's medical condition, (B) is expected to be ineffective based on the known relevant physical or mental characteristics of the insured and the known characteristics of the drug regimen, (C) will cause or will likely cause an adverse reaction by or physical harm to the insured, or (D) is not in the best interest of the insured, based on medical necessity.
Any such override process shall be convenient to use by health care providers and an override request shall be expeditiously granted when an insured's treating health care provider demonstrates that the drug regimen required under step therapy (A)has beenineffective inthepast for treatment oftheinsured's LCO No.
Any such override process shall be convenient to use by health care providers and an override request shall sHB6831 / File No.
3151 2 of 5 Raised Bill No.6831 medical condition, (B) is expected to be ineffective based on the known relevant physical or mental characteristics of the insured and the known characteristics of the drug regimen, (C) will cause or will likely cause an adverse reaction by or physical harm to the insured, or (D) is not in the best interest of the insured, based on medical necessity.
334 2 sHB6831 File No.
334 be expeditiously granted when an insured's treating health care provider demonstrates that the drug regimen required under step therapy (A)has beenineffective inthepast for treatment oftheinsured's medical condition, (B) is expected to be ineffective based on the known relevant physical or mental characteristics of the insured and the known characteristics of the drug regimen, (C) will cause or will likely cause an adverse reaction by or physical harm to the insured, or (D) is not in the best interest of the insured, based on medical necessity.
(1) One appointed by the speaker of the House of Representatives, who is a health care provider with expertise in mental health;
(1) One appointed by the speaker of the House of Representatives, who shall be a health care provider with expertise in mental health;
(2) One appointed by the president pro tempore of the Senate, who is a health care provider with expertise in mental health;
(2) One appointed by the president pro tempore of the Senate, who shall be a health care provider with expertise in mental health;
(3) One appointed by the minority leader of the House of Representatives, who is a health care provider with expertise in mental health;
(3) One appointed by the minority leader of the House of Representatives, who shall be a pharmacist licensed under chapter 400j of the general statutes;
(4) One appointed by the minority leader of the Senate, who is a health care provider with expertise in mental health;
(4) One appointed by the minority leader of the Senate, who shall be a representative of the pharmaceutical manufacturing industry;
(5) The chairpersons and ranking members of the joint standing committees of the General Assembly having cognizance of matters relating to public health and insurance, or their designees;
(5) The chairpersons and ranking members of the joint standing committees of the General Assembly having cognizance of matters sHB6831 / File No.
(6) The executive director of the Office of Health Strategy, or the LCO No.
334 3 sHB6831 File No.
3151 3 of 5 Raised Bill No.6831 executive director's designee;
334 relating to public health and insurance, or their designees;
(6) The executive director of the Office of Health Strategy, or the executive director's designee;
(c) The administrative staff of the joint standing committee of the General Assembly having cognizance of matters relating to public health shall serve as administrative staff of the task force.
(c) All initial appointments to the task force shall be made not later thanthirty daysafter theeffective date ofthis section.Any vacancy shall be filled by the appointing authority.
(d)NotlaterthanFebruary1,2024,thetaskforceshallsubmitareport on its findings and recommendations concerning subsection (a) of this section to thejoint standing committeesoftheGeneralAssembly having cognizance of matters relating to insurance and public health, in accordance with the provisions of section 11-4a of the general statutes.
(d) The speaker of the House of Representatives and the president pro tempore of the Senate shall select the chairpersons of the task force from among the members of the task force.
Such chairpersons shall schedule the first meeting of the task force, which shall be held not later than sixty days after the effective date of this section.
(e) The administrative staff of the joint standing committee of the sHB6831 / File No.
334 4 sHB6831 File No.
334 General Assembly having cognizance of matters relating to public health shall serve as administrative staff of the task force.
(f) Not later than February 1, 2024, the task force shall submit a report on its findings and recommendations concerning subsection (a) of this sectionto thejoint standing committeesoftheGeneralAssembly having cognizance of matters relating to insurance and public health, in accordance with the provisions of section 11-4a of the general statutes.
LCO No.
This act shall take effect as follows and shall amend the following sections:
3151 4 of 5 Raised Bill No.
6831 This act shall take effect as follows and shall amend the following sections:
3 from passage New section Statement of Purpose:
3 from passage New section INS Joint Favorable Subst.
To (1) allow providers to override step therapy for certain mental health conditions, and (2) establish a task force to study data collection efforts regarding step therapy.
sHB6831 / File No.
[Proposed deletions are enclosed in brackets.
334 5 sHB6831 File No.
Proposed additions are indicated by underline, except that when the entire text of a bill or resolution or a section of a bill or resolution is new, it is not underlined.] LCO No.
334 The following Fiscal Impact Statement and Bill Analysis are prepared for the benefit of the members of the General Assembly, solely for purposes of information, summarization and explanation and do not represent the intent of the General Assembly or either chamber thereof for any purpose.
3151 5 of 5
In general, fiscal impacts are based upon a variety of informational sources, including the analyst’s professional knowledge.
Whenever applicable, agency data is consulted as part of the analysis, however final products do not necessarily reflect an assessment from any specific department.
OFA Fiscal Note State Impact:
None Municipal Impact:
Municipalities Effect FY 24 $ FY 25 $ Various Municipalities Potential See Below See Below Cost Explanation The bill does not result in a fiscal impact to the state employee and retiree health plan or municipalities that participate in the Partnership Plan as step therapy is not required in the treatment of mental health conditionsoutlinedinthebill.Thesteptherapyoverrideprovisionsmay increase costs to certain fully insured municipal plans which currently require step therapy for treatment of schizophrenia, major depressive disorder, and bipolar disorder.
Section 3 establishes a task force to study data collection efforts regarding step therapy resulting in no fiscal impact to the state because the task force has the expertise to meet the requirements of the bill.
Show all 85 changed rows (45 more)
Previous
Latest
The Out Years The annualized ongoing fiscal impact identified above would continue into the future subject to inflation.
sHB6831 / File No.
334 6 sHB6831 File No.
334 OLR Bill Analysis sHB 6831 AN ACT CONCERNING THE OVERRIDE OF STEP THERAPY FOR CERTAIN MENTAL HEALTH CONDITIONS AND ESTABLISHING A TASK FORCE TO STUDY DATA COLLECTION EFFORTS REGARDING STEP THERAPY.
SUMMARY By law, health carriers (e.g., insurers and HMOs) that use step therapy (i.e., fail first protocols) for covering prescription drugs must have a process that they disclose to health care providers for overriding the step therapy process.
This bill requires health carriers to disclose the steptherapyoverrideprocesstoproviders inwritingatleastonceayear.
It also requires providers to display information about the override process in a conspicuous and prominent location, including on their website and an office bulletin board.
Additionally, from October 1, 2023, to October 1, 2026, the bill requires health carriers to grant a step therapy override request for drugs prescribed to treat schizophrenia, major depressive disorder, or bipolar disorder within 24 hours after a request is made.
Lastly, the bill establishes a 19-member task force to study step therapy data collection, including step therapy edits, rejections, and appeals for behavioral health drugs, and the best ways to collect data.
It requiresthetask force to report itsfindingsandrecommendationsto the Insurance and Real Estate and Public Health committees by February 1, 2024.
The task force terminateswhenit submitsitsreport or onFebruary 1, 2024, whichever is earlier.
EFFECTIVE DATE:
October 1, 2023, except the task force provisions are effective upon passage.
sHB6831 / File No.
334 7 sHB6831 File No.
334 STEP THERAPY TASK FORCE Under the bill, the task force includes the following members:
1.
two health care providers with mental health expertise, one each appointed by the House speaker and the Senate president pro tempore;
2.
one licensed pharmacist, appointed by the House minority leader;
3.
one pharmaceutical manufacturing industry representative, appointed by the Senate minority leader;
4.
the chairpersons and ranking members of the Insurance and Real Estate and Public Health committees, or their designees;
5.
the Office of Health Strategy executive director, or her designee;
6.
the insurance and consumer protection commissioners, or their designees;
7.
one insurance industry representative, appointed by the Insurance and Real Estate Committee’s House chairperson;
8.
one pharmaceutical industry representative, appointed by the Insurance and Real Estate Committee’s House ranking member;
9.
one mental health care provider, appointed by the Insurance and Real Estate Committee’s House chairperson;
and 10.
one mental health advocacy group representative who is an impacted individual, appointed by the Public Health Committee’s House ranking member.
The bill requires the appointing authorities to make their appointments within 30 days after the bill’s passage and fill any vacancies.
The bill also requires the House speaker and Senate president pro sHB6831 / File No.
334 8 sHB6831 File No.
334 tempore to select the task force’s chairpersons from among its members.
The chairpersons must schedule the first meeting, which must be held within 60 days after the bill’s passage.
The Public Health Committee’s administrative staff serve as the task force’s staff.
BACKGROUND Related Bill SB6, reported favorably by theInsurance and RealEstate Committee, prohibits health carriers from using step therapy for drugs prescribed to treat a behavioral health condition or a disabling, chronic, or life- threatening condition or disease.
COMMITTEE ACTION Insurance and Real Estate Committee Joint Favorable Substitute Yea 11 Nay 1 (03/14/2023) sHB6831 / File No.
334 9
View plain text versions (3)

Action History

  1. SENATE CALENDAR NUMBER 460

  2. FAV. RPT., TAB. FOR CAL., SEN.

  3. HOUSE PASSED

  4. FILE NO. 334

  5. HOUSE CALENDAR NUMBER 233

  6. FAV. RPT., TABLED FOR HOUSE CALENDAR

  7. RPTD. OUT OF LCO

  8. REFERRED TO Office of Legislative Research AND Office of Fiscal Analysis 03/29/23

  9. FILED WITH LCO

  10. Joint Favorable Substitute

  11. PUBLIC HEARING 0309

  12. REF. TO JOINT COMM. ON Insurance and Real Estate

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

6 sponsors · 0 co-sponsors · 181 not signed on

Sponsors (6)

Co-sponsors (0)

None.

Not signed on (181)

181 members have not signed on to this bill.

Show all 181 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

Who sponsors HB 6831?
HB 6831 is sponsored by Christie M. Carpino (Republican), Cook, Michelle L., Nicole Klarides-Ditria (Republican), Tom Delnicki (Republican), Robin E. Comey (Democratic), and Saud Anwar (Democratic).
What is the current status of HB 6831?
This bill died with 2023 Regular Session. It reached “Passed House” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
Where can I track HB 6831?
Track HB 6831 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on HB 6831

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Stay ahead of HB 6831

Last checked for changes 3 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →